See more : Europlasma SA (1EZ0.BE) Income Statement Analysis – Financial Results
Complete financial analysis of DICE Therapeutics, Inc. (DICE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DICE Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zeus Resources Limited (ZEU.AX) Income Statement Analysis – Financial Results
- Fujio Food Group Inc. (2752.T) Income Statement Analysis – Financial Results
- Zhejiang Oceanking Development Co., Ltd. (603213.SS) Income Statement Analysis – Financial Results
- Guizhou Panjiang Refined Coal Co.,Ltd. (600395.SS) Income Statement Analysis – Financial Results
- Vortex Brands Co. (VTXB) Income Statement Analysis – Financial Results
DICE Therapeutics, Inc. (DICE)
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.13M | 863.00K | 5.78M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 1.13M | 863.00K | 5.78M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 62.56M | 36.51M | 19.58M | 15.72M |
| General & Administrative | 25.66M | 12.22M | 5.00M | 3.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.66M | 12.22M | 5.00M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Cost & Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Interest Income | 5.21M | 136.00K | 139.00K | 635.00K |
| Interest Expense | 679.00K | 174.00K | 13.00K | 26.00K |
| Depreciation & Amortization | 5.21M | 136.00K | 836.00K | 1.34M |
| EBITDA | -83.01M | -47.47M | -22.89M | -12.21M |
| EBITDA Ratio | 0.00% | -4,219.29% | -2,651.80% | -211.36% |
| Operating Income | -88.22M | -47.60M | -23.72M | -13.55M |
| Operating Income Ratio | 0.00% | -4,231.38% | -2,748.67% | -234.58% |
| Total Other Income/Expenses | 4.33M | -1.36M | -18.00K | 609.00K |
| Income Before Tax | -83.89M | -48.96M | -23.74M | -12.94M |
| Income Before Tax Ratio | 0.00% | -4,351.91% | -2,750.75% | -224.03% |
| Income Tax Expense | -2.22M | -487.00K | 13.00K | 26.00K |
| Net Income | -81.66M | -48.47M | -23.75M | -12.96M |
| Net Income Ratio | 0.00% | -4,308.62% | -2,752.26% | -224.48% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39.40M | 12.38M | 23.23M | 23.23M |
| Weighted Avg Shares Out (Dil) | 39.40M | 12.38M | 23.23M | 23.23M |
Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push
Dice Therapeutics rallies as it agrees to be bought by Lilly
Eli Lilly to buy Dice Therapeutics in $2.4 billion deal
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
DICE Therapeutics psoriasis treatment has blockbuster potential, analysts say
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
DICE Therapeutics to Participate at Upcoming Investor Conferences
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Source: https://incomestatements.info
Category: Stock Reports